The medical product company recently received approval of two applications for patent protection of its babyLance(tm)
The Singapore patent is the second for babyLance. Last year, MediPurpose announced approval for another Singapore medical device patent in April 2011.
MediPurpose also holds multiple international medical device patents for its popular SurgiLance(tm)
The infant heelstick device's patent approval is currently pending in several other countries.
About babyLance Infant Heel Incision Devices
Originally introduced in July 2011, MediPurpose launched its all-new babyLance in August 2012.
The fully redesigned iteration of its original safe, easy and effective heelstick device was specifically designed to meet end-user requirements for an infant heel incision device that was easy to activate.
Used by neonatal caregivers to collect blood samples from infants, the new babyLance features an ergonomic design to provide a secure and stable grip.
Combined with a redesigned trigger mechanism, the heelstick device is easy to activate, helping to deliver a consistent incision without damaging the baby's tender nerve fibers.
babyLance heelstick devices are available in two models:
* The babyLance BLP (Preemie), which delivers an incision depth of 0.85 mm.
* The babyLance BLN (Newborn), which delivers an incision depth of 1.00 mm.
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance(tm)
MediPurpose's Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose's medical products and solutions for inventors, innovators, manufacturers and distributors, please visit http://www.medipurpose.com.